MX2022013658A - Inhibidores de la aldosa reductasa para tratar la deficiencia de sorbitol deshidrogenasa. - Google Patents

Inhibidores de la aldosa reductasa para tratar la deficiencia de sorbitol deshidrogenasa.

Info

Publication number
MX2022013658A
MX2022013658A MX2022013658A MX2022013658A MX2022013658A MX 2022013658 A MX2022013658 A MX 2022013658A MX 2022013658 A MX2022013658 A MX 2022013658A MX 2022013658 A MX2022013658 A MX 2022013658A MX 2022013658 A MX2022013658 A MX 2022013658A
Authority
MX
Mexico
Prior art keywords
reductase inhibitors
aldose reductase
treating
dehydrogenase deficiency
sorbitol dehydrogenase
Prior art date
Application number
MX2022013658A
Other languages
English (en)
Spanish (es)
Inventor
Shoshana Shendelman
Original Assignee
Applied Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Therapeutics Inc filed Critical Applied Therapeutics Inc
Publication of MX2022013658A publication Critical patent/MX2022013658A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2022013658A 2020-05-01 2021-04-27 Inhibidores de la aldosa reductasa para tratar la deficiencia de sorbitol deshidrogenasa. MX2022013658A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063019186P 2020-05-01 2020-05-01
US202063019738P 2020-05-04 2020-05-04
PCT/US2021/029286 WO2021222165A1 (en) 2020-05-01 2021-04-27 Aldose reductase inhibitors for treating sorbitol dehydrogenase deficiency

Publications (1)

Publication Number Publication Date
MX2022013658A true MX2022013658A (es) 2023-03-01

Family

ID=75954272

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013658A MX2022013658A (es) 2020-05-01 2021-04-27 Inhibidores de la aldosa reductasa para tratar la deficiencia de sorbitol deshidrogenasa.

Country Status (11)

Country Link
US (2) US20230121312A1 (enExample)
EP (1) EP4135674A1 (enExample)
JP (2) JP7788399B2 (enExample)
KR (1) KR20230005944A (enExample)
CN (1) CN115996725A (enExample)
AU (1) AU2021264454A1 (enExample)
BR (1) BR112022021845A2 (enExample)
CA (1) CA3176768A1 (enExample)
IL (1) IL297779A (enExample)
MX (1) MX2022013658A (enExample)
WO (1) WO2021222165A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL272246B2 (en) 2017-07-28 2026-01-01 Applied Therapeutics Inc History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications
CA3132136A1 (en) 2019-04-01 2020-10-08 Andrew Wasmuth Inhibitors of aldose reductase
JP2022531466A (ja) 2019-05-07 2022-07-06 ユニバーシティ オブ マイアミ 遺伝性ニューロパチーおよび関連障害の処置および検出
GB202400033D0 (en) 2024-01-02 2024-02-14 Nicolnson Tamara Therapy i
WO2025219948A1 (en) * 2024-04-17 2025-10-23 Assia Chemical Industries Ltd. Crystalline forms of govorestat

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4939140A (en) 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
JPH0495025A (ja) 1990-08-08 1992-03-27 Asahi Chem Ind Co Ltd アルドースリダクターゼ阻害剤
US5464961A (en) 1993-09-10 1995-11-07 Olin Corporation Arcjet anode
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
JPH11512095A (ja) 1995-08-28 1999-10-19 アメリカン・ホーム・プロダクツ・コーポレイション アルドース還元酵素阻害薬および抗高血糖症薬としてのフェノキシ酢酸
PL179170B1 (pl) 1995-09-15 2000-07-31 Inst Lekow Nowe zwiazki,pochodne genisteiny PL PL PL PL
SI0776895T1 (en) 1995-11-20 1999-04-30 Eli Lilly And Company Protein kinase C inhibitor
WO1998042324A2 (en) * 1997-03-21 1998-10-01 The Regents Of The University Of California Methods for modulating neurotrophic factor-associated activity using aldose reductase inhibitors
GB9714274D0 (en) * 1997-07-08 1997-09-10 Zeneca Ltd Pharmaceutical composition
EP0982306A3 (en) 1998-08-21 2000-07-05 Pfizer Products Inc. Polymorph of zopolrestat monohydrate
US6570013B2 (en) 2000-02-16 2003-05-27 Pfizer Inc Salts of zopolrestat
WO2003105864A1 (en) 2002-06-13 2003-12-24 Board Of Regents, The University Of Texas System Methods and compositions involving aldose reductase inhibitors
EP2065038A1 (en) * 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
HRP20221430T1 (hr) 2010-07-16 2023-01-06 The Trustees Of Columbia University In The City Of New York Inhibitori aldozoreduktaze i njihova uporaba
WO2017038505A1 (ja) 2015-09-01 2017-03-09 株式会社村田製作所 コイル内蔵部品
RS61239B1 (sr) * 2016-06-21 2021-01-29 Univ Columbia Inhibitori aldozne reduktaze i postupci korišćenja
IL272246B2 (en) * 2017-07-28 2026-01-01 Applied Therapeutics Inc History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications

Also Published As

Publication number Publication date
US20230121312A1 (en) 2023-04-20
BR112022021845A2 (pt) 2022-12-20
JP2023524504A (ja) 2023-06-12
JP7788399B2 (ja) 2025-12-18
EP4135674A1 (en) 2023-02-22
US20240238288A1 (en) 2024-07-18
IL297779A (en) 2022-12-01
AU2021264454A1 (en) 2022-12-08
CA3176768A1 (en) 2021-11-04
WO2021222165A1 (en) 2021-11-04
KR20230005944A (ko) 2023-01-10
CN115996725A (zh) 2023-04-21
JP2026012262A (ja) 2026-01-23

Similar Documents

Publication Publication Date Title
MX2022013658A (es) Inhibidores de la aldosa reductasa para tratar la deficiencia de sorbitol deshidrogenasa.
EP4234587A3 (en) Thermally inhibited starch and process for making
WO2009100406A3 (en) Topical formulations for the treatment of psoriasis
ZA201802331B (en) Stable inoculant compositions and methods for producing same
MY187588A (en) Compositions and methods for rapid and dynamic flux control using synthetic metabolic valves
MX2021007474A (es) Homoserina deshidrogenasa modificada y procedimiento para la produccion de homoserina o l-aminoacido derivado de homoserina mediante el uso de la misma.
MX2019002069A (es) Metodo para la fabricacion de partes de acero revestidas, endurecidas por presion y laminas de acero pre-revestidas que pueden ser utilizadas para la fabricacion de dichas partes.
PH12019502892A1 (en) Mitoketoscins: mitochondrial-based therapeutics targeting ketone metabolism in cancer cells
WO2009063312A3 (en) Nucleic acid sequences encoding transcription factors regulating alkaloid biosynthesis and their use in modifying plant metabolism
EP4446338A3 (en) Cells and method of cell culture
NZ738659A (en) Microorganisms for producing putrescine or ornithine and process for producing putrescine or ornithine using them
MX2022001491A (es) Factor de transcripcion nterf221 y metodos de uso del mismo.
AU2018274709A1 (en) Methods for increasing grain productivity
MY187786A (en) N-acetyl homoserine
PH12019501779A1 (en) Method and device for producing biogas
WO2012090554A8 (ja) 微生物の新規な培養方法、新規な元素構成を有する微生物細胞を製造する方法、及び製造された微生物
EP4559526A3 (en) Composition for regulating cancer cell division or differentiation comprising setdb1 or a setdb1 inhibitor
WO2021076817A3 (en) Methods and compositions related to treatment and prevention of cancer by inhibition of dgat1 and dgat2
MY186400A (en) Eukaryotic cell with increased production of fermentation product
MX2023012903A (es) Metodo para producir spesolimab.
MX2024002049A (es) Terapia de modulacion personalizada para cancer.
MX2023004254A (es) La ingeniería genética aumentó los niveles de suberina al alterar los patrones de expresión génica de una manera específica de tipo celular.
MX2024015744A (es) Proteina de exportacion de l-histidina y metodo de produccion de l-histidina utilizando la misma
WO2013173412A3 (en) Engineered yeast for production of renewable chemicals
BR112019007017A2 (pt) inibidor de crescimento bacteriano, fúngico e de levedura contendo alulose